Literature DB >> 20496097

Differentiating effects of the glucagon-like peptide-1 analogue exendin-4 in a human neuronal cell model.

Paola Luciani1, Cristiana Deledda, Susanna Benvenuti, Ilaria Cellai, Roberta Squecco, Monica Monici, Francesca Cialdai, Giorgia Luciani, Giovanna Danza, Chiara Di Stefano, Fabio Francini, Alessandro Peri.   

Abstract

Glucagon-like peptide-1 (GLP-1) is an insulinotropic peptide with neurotrophic properties, as assessed in animal cell models. Exendin-4, a GLP-1 analogue, has been recently approved for the treatment of type 2 diabetes mellitus. The aim of this study was to morphologically, structurally, and functionally characterize the differentiating actions of exendin-4 using a human neuronal cell model (i.e., SH-SY5Y cells). We found that exendin-4 increased the number of neurites paralleled by dramatic changes in intracellular actin and tubulin distribution. Electrophysiological analyses showed an increase in cell membrane surface and in stretch-activated-channels sensitivity, an increased conductance of Na(+) channels and amplitude of Ca(++) currents (T- and L-type), typical of a more mature neuronal phenotype. To our knowledge, this is the first demonstration that exendin-4 promotes neuronal differentiation in human cells. Noteworthy, our data support the claimed favorable role of exendin-4 against diabetic neuropathy as well as against different neurodegenerative diseases.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20496097     DOI: 10.1007/s00018-010-0398-3

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  60 in total

Review 1.  GLP-1 and extra-islet effects.

Authors:  B Ahrén
Journal:  Horm Metab Res       Date:  2004 Nov-Dec       Impact factor: 2.936

2.  Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats.

Authors:  M Tang-Christensen; P J Larsen; R Göke; A Fink-Jensen; D S Jessop; M Møller; S P Sheikh
Journal:  Am J Physiol       Date:  1996-10

Review 3.  Mechanisms of action of glucagon-like peptide 1 in the pancreas.

Authors:  Máire E Doyle; Josephine M Egan
Journal:  Pharmacol Ther       Date:  2006-12-28       Impact factor: 12.310

4.  Caffeine activates the PI3K/Akt pathway and prevents apoptotic cell death in a Parkinson's disease model of SH-SY5Y cells.

Authors:  Kazuhiro Nakaso; Satoru Ito; Kenji Nakashima
Journal:  Neurosci Lett       Date:  2007-12-23       Impact factor: 3.046

5.  Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1.

Authors:  B Thorens
Journal:  Proc Natl Acad Sci U S A       Date:  1992-09-15       Impact factor: 11.205

6.  Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells.

Authors:  K Moens; H Heimberg; D Flamez; P Huypens; E Quartier; Z Ling; D Pipeleers; S Gremlich; B Thorens; F Schuit
Journal:  Diabetes       Date:  1996-02       Impact factor: 9.461

7.  Role of L-type Ca2+ channels in neural stem/progenitor cell differentiation.

Authors:  Marcello D'Ascenzo; Roberto Piacentini; Patrizia Casalbore; Manuela Budoni; Roberto Pallini; Gian Battista Azzena; Claudio Grassi
Journal:  Eur J Neurosci       Date:  2006-02       Impact factor: 3.386

8.  Impact of the selective estrogen receptor modulator, raloxifene, on neuronal survival and outgrowth following toxic insults associated with aging and Alzheimer's disease.

Authors:  Kathleen O'Neill; Shuhua Chen; Roberta Diaz Brinton
Journal:  Exp Neurol       Date:  2004-01       Impact factor: 5.330

9.  Retinoic acid-induced neuritogenesis of human neuroblastoma SH-SY5Y cells is ERK independent and PKC dependent.

Authors:  Mariarosaria Miloso; Daniela Villa; Marco Crimi; Stefania Galbiati; Elisabetta Donzelli; Gabriella Nicolini; Giovanni Tredici
Journal:  J Neurosci Res       Date:  2004-01-15       Impact factor: 4.164

10.  Gut-expressed gustducin and taste receptors regulate secretion of glucagon-like peptide-1.

Authors:  Hyeung-Jin Jang; Zaza Kokrashvili; Michael J Theodorakis; Olga D Carlson; Byung-Joon Kim; Jie Zhou; Hyeon Ho Kim; Xiangru Xu; Sic L Chan; Magdalena Juhaszova; Michel Bernier; Bedrich Mosinger; Robert F Margolskee; Josephine M Egan
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-27       Impact factor: 11.205

View more
  19 in total

Review 1.  Cardiovascular autonomic neuropathies as complications of diabetes mellitus.

Authors:  Michael Kuehl; Martin J Stevens
Journal:  Nat Rev Endocrinol       Date:  2012-02-28       Impact factor: 43.330

2.  Liraglutide Promotes Cortical Neurite Outgrowth via the MEK-ERK Pathway.

Authors:  Meng Li; Shilun Li; Yukun Li
Journal:  Cell Mol Neurobiol       Date:  2015-04-11       Impact factor: 5.046

Review 3.  Neuroprotective and neurotrophic actions of glucagon-like peptide-1: an emerging opportunity to treat neurodegenerative and cerebrovascular disorders.

Authors:  Isidro Salcedo; David Tweedie; Yazhou Li; Nigel H Greig
Journal:  Br J Pharmacol       Date:  2012-07       Impact factor: 8.739

Review 4.  The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: An in-depth review.

Authors:  Niklas Reich; Christian Hölscher
Journal:  Front Neurosci       Date:  2022-09-01       Impact factor: 5.152

5.  GLP-1R activation for the treatment of stroke: updating and future perspectives.

Authors:  Vladimer Darsalia; David Nathanson; Thomas Nyström; Thomas Klein; Åke Sjöholm; Cesare Patrone
Journal:  Rev Endocr Metab Disord       Date:  2014-09       Impact factor: 6.514

6.  Effects of exenatide on measures of diabetic neuropathy in subjects with type 2 diabetes: results from an 18-month proof-of-concept open-label randomized study.

Authors:  Mamta Jaiswal; Catherine L Martin; Morton B Brown; Brian Callaghan; James W Albers; Eva L Feldman; Rodica Pop-Busui
Journal:  J Diabetes Complications       Date:  2015-07-17       Impact factor: 2.852

Review 7.  Non-glucose risk factors in the pathogenesis of diabetic peripheral neuropathy.

Authors:  Kyung Ae Lee; Tae Sun Park; Heung Yong Jin
Journal:  Endocrine       Date:  2020-09-07       Impact factor: 3.633

8.  Exendin-4 induces cell adhesion and differentiation and counteracts the invasive potential of human neuroblastoma cells.

Authors:  Paola Luciani; Cristiana Deledda; Susanna Benvenuti; Roberta Squecco; Ilaria Cellai; Benedetta Fibbi; Ilaria Maddalena Marone; Corinna Giuliani; Giulia Modi; Fabio Francini; Gabriella Barbara Vannelli; Alessandro Peri
Journal:  PLoS One       Date:  2013-08-22       Impact factor: 3.240

9.  Exendin-4 ameliorates traumatic brain injury-induced cognitive impairment in rats.

Authors:  Katharine Eakin; Yazhou Li; Yung-Hsiao Chiang; Barry J Hoffer; Hilary Rosenheim; Nigel H Greig; Jonathan P Miller
Journal:  PLoS One       Date:  2013-12-02       Impact factor: 3.240

10.  Neuroprotection of Exendin-4 by Enhanced Autophagy in a Parkinsonian Rat Model of α-Synucleinopathy.

Authors:  Lu-Lu Bu; Yan Shen; Yi-Qi Liu; Yun Fan; Wen-Bo Yu; Dong-Lang Jiang; Yi-Lin Tang; Yu-Jie Yang; Ping Wu; Chuan-Tao Zuo; James B Koprich; Feng-Tao Liu; Jian-Jun Wu; Jian Wang
Journal:  Neurotherapeutics       Date:  2021-03-15       Impact factor: 7.620

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.